ArticlePloS one2013
HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Article
- A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design.The Journal of experimental medicine · 2023Article
- H2-O deficiency promotes regulatory T cell differentiation and CD4 T cell hyperactivity.Frontiers in immunology · 2023Article
- Proper development of long-lived memory CD4 T cells requires HLA-DO function.Frontiers in immunology · 2023Article
- Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.Current opinion in immunology · 2021Review
- Lysosomal cathepsin creates chimeric epitopes for diabetogenic CD4 T cells via transpeptidation.The Journal of experimental medicine · 2021Article
- How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?Frontiers in immunology · 2021Review
- The love and hate relationship of HLA-DM/DO in the selection of immunodominant epitopes.Current opinion in immunology · 2020Review
- Lack of the MHC class II chaperone H2-O causes susceptibility to autoimmune diseases.PLoS biology · 2020Article
- How a Proposed Hypothesis during My PhD Training Shaped My Career.Critical reviews in immunology · 2020Article
- Synergy between B cell receptor/antigen uptake and MHCII peptide editing relies on HLA-DO tuning.Scientific reports · 2019Article
- Selection of immunodominant epitopes during antigen processing is hierarchical.Molecular immunology · 2019Review
- Structural aspects of chaperone-mediated peptide loading in the MHC-I antigen presentation pathway.Critical reviews in biochemistry and molecular biology · 2019Review
- HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.Molecular & cellular proteomics : MCP · 2019Article
- What to do with HLA-DO/H-2O two decades later?Immunogenetics · 2019Review
- A Missing Switch in Peptide Exchange for MHC Class II Molecules.Frontiers in immunology · 2019Review
- Protein-Specific Features Associated with Variability in Human Antibody Responses toThe American journal of tropical medicine and hygiene · 2018Article
- Distorted Immunodominance by Linker Sequences or other Epitopes from a Second Protein Antigen During Antigen-Processing.Scientific reports · 2017Article
- The Other Function: Class II-Restricted Antigen Presentation by B Cells.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Processing of antigens for presentation to helper T cells by MHC class II involves HLA-DM (DM) and HLA-DO (DO) accessory molecules. A mechanistic understanding of DO in this process has been missing. The leading model on its function proposes that DO inhibits the effects of DM. To directly study DO functions, we designed a recombinant soluble DO and expressed it in insect cells. The kinetics of binding and dissociation of several peptides to HLA-DR1 (DR1) molecules in the presence of DM and DO were measured. We found that DO reduced binding of DR1 to some peptides, and enhanced the binding of some other peptides to DR1. Interestingly, these enhancing and reducing effects were observed in the presence, or absence, of DM. We found that peptides that were negatively affected by DO were DM-sensitive, whereas peptides that were enhanced by DO were DM-resistant. The positive and negative effects of DO could only be measured on binding kinetics as peptide dissociation kinetics were not affected by DO. Using Surface Plasmon Resonance, we demonstrate direct binding of DO to a peptide-receptive, but not a closed conformation of DR1. We propose that DO imposes another layer of control on epitope selection during antigen processing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.